Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Turner

Showing results (221-230 of 362) with videos related to

Pageof 37
Sort By:
Inflammatory Bowel Diseases|June 13, 2025
Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label TrialDotan Yogev, Yael Weintraub, Oren Ledder, et al.
Clinical Transplantation|September 10, 2021
Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccineAyelet Grupper, Eugene Katchman, Merav Ben-Yehoyada, et al.
Journal of Crohn'S & Colitis|September 19, 2025
Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort studyOmer Rotem-Tryfus, Ben Kang, Esther Orlanski-Meyer, et al.
The Lancet. Gastroenterology & Hepatology|October 28, 2022
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort studyOhad Atia, Zivia Shavit-Brunschwig, Diane R Mould, et al.
Alimentary Pharmacology & Therapeutics|January 15, 2025
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre StudyRonen Stein, Dan Turner, Séamus Hussey, et al.
Inflammatory Bowel Diseases|January 8, 2026
Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 StudyDan Turner, Kathleen G Lomax, Gigi Veereman, et al.
Inflammatory Bowel Diseases|October 17, 2024
Gut Microbial Signatures in Pediatric Crohn's Disease Vary According to Disease Activity Measures and Are Influenced by Proxies of Gastrointestinal Transit Time: An ImageKids StudyBen Nichols, Richard K Russell, Bryn Short, et al.
Inflammatory Bowel Diseases|May 20, 2024
Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRNOhad Atia, Rachel Buchuk, Rona Lujan, et al.
Crohn'S & Colitis 360|May 5, 2025
Ethnic Disparities in the Management of Inflammatory Bowel Disease in Israel and Impact on OutcomesElad Boaz, Oren Ledder, Ariella Bar-Gil Shitrit, et al.
Inflammatory Bowel Diseases|May 3, 2016
pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHANLiron Birimberg-Schwartz, David C Wilson, Kaija-Leena Kolho, et al.
Pageof 37

Showing results (221-230 of 362) with videos related to

Sort By:
Pageof 37
Inflammatory Bowel Diseases|June 13, 2025
Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label TrialDotan Yogev, Yael Weintraub, Oren Ledder, et al.
Clinical Transplantation|September 10, 2021
Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccineAyelet Grupper, Eugene Katchman, Merav Ben-Yehoyada, et al.
Journal of Crohn'S & Colitis|September 19, 2025
Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort studyOmer Rotem-Tryfus, Ben Kang, Esther Orlanski-Meyer, et al.
The Lancet. Gastroenterology & Hepatology|October 28, 2022
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort studyOhad Atia, Zivia Shavit-Brunschwig, Diane R Mould, et al.
Alimentary Pharmacology & Therapeutics|January 15, 2025
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre StudyRonen Stein, Dan Turner, Séamus Hussey, et al.
Inflammatory Bowel Diseases|January 8, 2026
Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 StudyDan Turner, Kathleen G Lomax, Gigi Veereman, et al.
Inflammatory Bowel Diseases|October 17, 2024
Gut Microbial Signatures in Pediatric Crohn's Disease Vary According to Disease Activity Measures and Are Influenced by Proxies of Gastrointestinal Transit Time: An ImageKids StudyBen Nichols, Richard K Russell, Bryn Short, et al.
Inflammatory Bowel Diseases|May 20, 2024
Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRNOhad Atia, Rachel Buchuk, Rona Lujan, et al.
Crohn'S & Colitis 360|May 5, 2025
Ethnic Disparities in the Management of Inflammatory Bowel Disease in Israel and Impact on OutcomesElad Boaz, Oren Ledder, Ariella Bar-Gil Shitrit, et al.
Inflammatory Bowel Diseases|May 3, 2016
pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHANLiron Birimberg-Schwartz, David C Wilson, Kaija-Leena Kolho, et al.
Pageof 37